

**COMPLETION OF UNMARKETABLE PARCEL SHARE BUY-BACK**

MELBOURNE, 10 February 2021: On 14 December 2020, Anatara Lifesciences Limited (**Anatara**) (ASX: ANR) announced details of an off-market share buy-back facility (**Buy-Back Facility**) to buy-back all of the shares held by shareholders who held unmarketable parcels of shares in the Company (**Eligible Shareholders**) as at 7:00 p.m. (Melbourne time) on Friday, 11 December 2020 (**Record Date**).

In accordance with the terms of the Buy-Back Facility, Eligible Shareholders had until 7:00pm (Melbourne time) Friday, 5 February 2021 to opt-out of the Buy-Back Facility or increase their shareholding to more than a marketable parcel. This was extended to 12:00 noon on Monday 8 February 2021 to allow for postage time (**Closing Time**). Eligible Shareholders that did not exercise either of these options by the Closing Time had their Anatara shares bought back by the Company at \$0.178 per share (**Buy-Back Price**), being the volume-weighted average price for the five-day trading period preceding the Record Date.

A total of 211,413 Anatara shares have been acquired under the Buy-Back Facility at the Buy-Back Price and have been cancelled in accordance with the *Corporations Act 2001* (Cth). As a result, Anatara now has 70,238,523 fully paid ordinary shares on issue. In accordance with the requirements of the ASX Listing Rule 3.8A, enclosed is a copy of the Form 484 lodged with the Australian Securities and Investments Commission.

Eligible Shareholders whose Shares were brought back under the Buy-Back Facility will have their proceeds remitted to them and will be sent documentation advising them of the number of shares sold and the amount of proceeds remitted as soon as practicable following 12 February 2021.

For further information, please contact the Anatara Buy-Back Information Line on 1300 850 505 (from within Australia) or +61 3 9415 4000 (from outside Australia) between Monday, 10 February 2021 and Friday, 19 February 2021, between the hours of 8:30 a.m. to 5:00 p.m. Monday – Friday (Melbourne time).

This announcement has been authorised by Anatara's Board of Directors.

For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair, Anatara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anatara.com

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited

Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anatara.com | Website anataralifesciences.com



Change to company details

Company details

Company name

ANATARA LIFESCIENCES LTD

Australian Company Number (ACN)

145 239 872

Lodgement details

Who should ASIC contact if there is a query about this form?

Name

Stephen Anthony DENARO

Signature

This form must be signed by a current officeholder of the company.

I certify that the information in this form is true and complete

Name

Stephen Anthony DENARO

Capacity

Secretary

Signature

Date signed

10-02-2021

C1 Cancellation of shares

Reason for cancellation

Shares cancellation details

Reason for cancellation

**ss.257H(3) Share buyback - Minimum holding
buy-back only**

The cancelled shares are listed below:

Share class code	Number of shares cancelled	Amount paid (cash or otherwise)	
ORD	211413	37631.51	

Earliest Date of
cancellation

09-02-2021

C3 Change to share structure

The updated details for this changed share class are shown in the table below.

Share class code	Full title if not standard	Total number of shares	Total amount paid on these shares	Total amount unpaid on these shares
ORD	ORDINARY	70238523	21170146.49	0.00

Earliest date of
change

09-02-2021